Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
International Journal of General Medicine
|
October 28, 2021
High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcalá, Spain: Contributing Factors
Ramón Pérez-Tanoira, Lourdes Lledó García, Miguel Torralba González de Suso, et al.
The Journal of Antimicrobial Chemotherapy
|
October 6, 2019
Factors associated with the number of drugs in darunavir/cobicistat regimens
Esteban Martinez, Eugenia Negredo, Hernando Knobel, et al.
The Annals of Pharmacotherapy
|
May 3, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain
Miguel Torralba, Gema Rodríguez, Francisco Javier González Gasca, et al.
Plos One
|
February 18, 2026
Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy
Jose-Ramon Blanco, Miguel Torralba, María Saumoy, et al.
HIV Medicine
|
October 7, 2025
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis
Gundolf Schuettfort, Jan Borch, Alfonso Cabello, et al.
Journal of Infection and Public Health
|
March 20, 2026
Use of long-acting therapies for the HIV treatment in the Spanish pediatric cohort (CoRISpe)
Beatriz Lazaro-Martin, Laura Tarancon-Diez, Joaquín Burgos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 10, 2025
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)
Sergio Serrano-Villar, Laura Martín-Pedraza, Juan Tiraboschi, et al.
HIV Medicine
|
October 21, 2025
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort
Jesús Troya, María Luisa Montes, María José Galindo, et al.
The Journal of Infection
|
August 6, 2025
Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024)
Alejandra González-Sánchez, Cristina Andrés, Ignasi Prats-Méndez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 3, 2024
Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol
Félix Gutiérrez, Leandro López, Carlos Galera, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
International Journal of General Medicine
|
October 28, 2021
High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcalá, Spain: Contributing Factors
Ramón Pérez-Tanoira, Lourdes Lledó García, Miguel Torralba González de Suso, et al.
The Journal of Antimicrobial Chemotherapy
|
October 6, 2019
Factors associated with the number of drugs in darunavir/cobicistat regimens
Esteban Martinez, Eugenia Negredo, Hernando Knobel, et al.
The Annals of Pharmacotherapy
|
May 3, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain
Miguel Torralba, Gema Rodríguez, Francisco Javier González Gasca, et al.
Plos One
|
February 18, 2026
Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy
Jose-Ramon Blanco, Miguel Torralba, María Saumoy, et al.
HIV Medicine
|
October 7, 2025
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis
Gundolf Schuettfort, Jan Borch, Alfonso Cabello, et al.
Journal of Infection and Public Health
|
March 20, 2026
Use of long-acting therapies for the HIV treatment in the Spanish pediatric cohort (CoRISpe)
Beatriz Lazaro-Martin, Laura Tarancon-Diez, Joaquín Burgos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 10, 2025
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)
Sergio Serrano-Villar, Laura Martín-Pedraza, Juan Tiraboschi, et al.
HIV Medicine
|
October 21, 2025
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort
Jesús Troya, María Luisa Montes, María José Galindo, et al.
The Journal of Infection
|
August 6, 2025
Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024)
Alejandra González-Sánchez, Cristina Andrés, Ignasi Prats-Méndez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 3, 2024
Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol
Félix Gutiérrez, Leandro López, Carlos Galera, et al.
Page
of 8